ArticleJournal of applied clinical medical physics2026
Log file-based treatment efficiency analysis of TrueBeam and Halcyon delivery systems.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrueBeam (TB) and Halcyon (HC) are state-of-the-art linear accelerators (linacs) widely utilized for external beam radiotherapy. As clinical demand increases, expanding treatment capacity through new machine installations or extended operating hours remains costly and resource intensive. Retrospective analyses of treatment delivery performance can help guide machine assignment strategies that optimize machine utilization, reduce patient time alone on the treatment couch, and improve overall departmental throughput. PURPOSE: To introduce a trajectory log-based methodology for assessing treatment delivery efficiency on Halcyon and TrueBeam systems by quantifying gantry speed, MLC speed, and dose-rate utilization, and to integrate these machine-level parameters with beam-on time and modulation factor (MF) to guide treatment machine assignment and patient triaging.
methodsVolumetric modulated arc therapy (VMAT) trajectory logs acquired between February 2025 and February 2026 were collected from fourteen clinical linacs across a main institution and its affiliated regional clinics. The percentages of beam-on time during which the machine operated at ≥95% of its maximum dose rate (max_DR), gantry speed (max_GS), or MLC speed (max_MLC) were quantified. Plans were categorized by procedure type and disease site, and delivery efficiencies were compared using Mann-Whitney U test.
resultsA total of 4347 VMAT plans were included in the study. For stereotactic body radiation therapy (SBRT) plans, Halcyon had a significantly higher max_DR (0.96 ± 0.14 vs. 0.51 ± 0.39 for TrueBeam), suggesting its max dose rate might be a bottleneck for treatment efficiency. For non-SBRT plans, Halcyon demonstrated greater max_GS (0.68 ± 0.32 vs. 0.43 ± 0.22 for TrueBeam) and max_MLC (0.66 ± 0.32 vs. 0.38 ± 0.23 for TrueBeam), which is reflected in its higher MF and faster beam-on time compared to TrueBeam, saving over 50 seconds of on-table time per plan for each patient.
conclusionsHalcyon demonstrates superior delivery efficiency for non-SBRT plans compared to TrueBeam through higher usage of its maximum MLC speed and gantry speed throughout treatment, especially for pelvis plans. In contrast, TrueBeam has significantly shorter beam-on time for higher-dose treatments (e.g. prostate SBRT), likely due to its higher nominal maximum dose rates at flattening filter-free energies. By linking delivery performance to underlying machine-specific limitations, this work provides a transferable framework for machine efficiency assessment that can be readily implemented at other centers using trajectory log data to guide machine assignment decisions and evaluate the potential impact of future Linac technology advancements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.